Jacobs Levy Equity Management Inc. Acquires Shares of 357,248 Stoke Therapeutics, Inc. $STOK

Key Points

• Jacobs Levy Equity Management Inc. acquired a new stake in Stoke Therapeutics, purchasing 357,248 shares valued at approximately $2.4 million, representing 0.65% ownership of the company.
• A variety of institutional investors have also increased their stakes in Stoke Therapeutics, with notable transactions including a new position worth $35 million from Toronto Dominion Bank.
• Stoke Therapeutics recently reported quarterly earnings, exceeding expectations with a loss of $0.40 per share against a consensus estimate of $0.57, alongside revenue of $13.82 million, which fell short of the $31.51 million estimate.

Jacobs Levy Equity Management Inc. bought a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 357,248 shares of the company's stock, valued at approximately $2,376,000. Jacobs Levy Equity Management Inc. owned approximately 0.65% of Stoke Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in Stoke Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock valued at $904,000 after purchasing an additional 1,148 shares in the last quarter. Graham Capital Management L.P. grew its position in Stoke Therapeutics by 8.5% in the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock valued at $206,000 after purchasing an additional 1,453 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Stoke Therapeutics by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock valued at $414,000 after acquiring an additional 2,215 shares during the period. Group One Trading LLC increased its stake in shares of Stoke Therapeutics by 2.8% during the 4th quarter. Group One Trading LLC now owns 104,411 shares of the company's stock worth $1,152,000 after purchasing an additional 2,837 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Stoke Therapeutics by 16.2% during the 4th quarter. California State Teachers Retirement System now owns 32,068 shares of the company's stock worth $354,000 after purchasing an additional 4,468 shares during the last quarter.

Stoke Therapeutics Stock Performance

Shares of STOK stock traded down $0.42 during midday trading on Friday, hitting $23.46. 1,030,859 shares of the company were exchanged, compared to its average volume of 957,451. The firm has a market capitalization of $1.29 billion, a P/E ratio of 27.60 and a beta of 1.14. The firm's 50 day moving average price is $16.05 and its two-hundred day moving average price is $11.52. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $24.60.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. The business had revenue of $13.82 million during the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. Analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a research note on Friday, July 18th. They set a "buy" rating and a $30.00 price objective on the stock. BTIG Research set a $28.00 price objective on shares of Stoke Therapeutics and gave the stock a "buy" rating in a research note on Monday, August 18th. Wedbush boosted their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 13th. Chardan Capital restated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Two analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $25.57.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 5,501 shares of the business's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $19.87, for a total value of $109,304.87. Following the completion of the sale, the insider owned 18,469 shares of the company's stock, valued at $366,979.03. The trade was a 22.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Jonathan Allan sold 6,345 shares of the business's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $20.07, for a total transaction of $127,344.15. Following the completion of the sale, the general counsel directly owned 11,831 shares of the company's stock, valued at $237,448.17. This represents a 34.91% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 107,719 shares of company stock valued at $2,063,359. Company insiders own 9.50% of the company's stock.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.